Venous thromboembolism (VTE) also known as deep vein thrombosis, occurs when blood clots the deep veins of legs, arms, gorin. Globally, VTE is one the leading cause of disability and death. Although exact number of individuals suffering from venous thromboembolism is not documented.
According to Centers of Disease Control and Prevention States, approximately each year 900,000 people could be affected (1or 2 per 1,000) in the U.S. Also, CDC states that approximately 60,000 -100,000 Americans die due to venous thromboembolism. Also, some 10-30% of the people will die within the initial one month of diagnosis.
Get Sample Copy of this [email protected] https://www.persistencemarketresearch.com/samples/32628
Also, part from the disease burden, VTE also can lead to economic burden. Prolonged hospital stays and follow up care including recurrent VTE, can be heavy on pockets. For instance, In the U.S., the associated cost with the diagnosis and treatment costs US $ 15.5 billion per year, while in the U.K. VTE costs the National Health Services €640 million per year.
Also, the pacific regions are expected to witness the burden associated with the VTE, which is estimated to be at US $1.72 billion a year. Also, when loss of well-being such as disability and premature death are included, the can annual cost can rise to US $ 19.99 billion (Source: International Society on Thrombosis and Haemostasis).
Thus, high number of cases and economic burden associated with the VTE demands the enhance care which can improve the blood flow and mobility among the patients. Factors such as these are expected to drive the sales of the muscle pump activators.